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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hemato-
poietic precursor cell tumor formerly known as CD4+/CD56+
hematodermic neoplasm or blastic NK-cell lymphoma. BPDCN is de-
rived from precursors of plasmacytoid dendritic cells and disease con-
cept was established by the revised World Health Organization
classiﬁcation in 2008. It is diagnosed by its blastic or plasmacytoid mor-
phology and expression of CD4 and CD56 [1]. Confusion can also arise as
the CD4 antigen may be expressed in 82% by leukemic monocytes to-
gether with CD56 antigen which can be positive in up to 71% of mono-
cytic blast cells. In such cases beside CD4 and CD56 speciﬁc dendritic cell
markers CD123 (interleukin-3 α-chain), BDCA-2/CD303 (blood den-
dritic cell antigen-2), TCL1, and SPIB [2–5] should be used to make dif-
ferential diagnosis between these two entities.
BPDCN is characterized by a rapid and aggressive malignant clinical
course and usually has an extremely poor prognosis, with quick relapse
after chemotherapy [6]. One of themost important symptoms of BPDCN
is skin lesions being the hallmark of disease presentation [7]. The path-
ogenesis of BPDCN is not well understood, and little is currently known
about the genetic features of this disease entity.
Here we report a male patient who presented with bonemarrow le-
sions with some immunophenotypic features overlapping BPDCN and
myeloid neoplasm,who during the next fewmonths developed atypical
myeloid neoplasm resistant to chemotherapy with a rapidly fatal
course.2. Case report
67 year old male with past medical history of coronary artery dis-
ease, hypertension and diabetes mellitus presented to our emergency
room with a fever, weakness, fatigue and dizziness associated with
back pain. On admission, fever was conﬁrmed (39 °C) and ﬁndings
from a physical examination were normal. Initial laboratory tests
showed anemia and thrombocytopenia. He was noted to have very
high LDH and ferritin (Table 1). Peripheral blood smear was unremark-
able. Blood and urine cultures showed no infection. Abdominal CT
showed enlarged spleenwithout focal lesionsmeasuring approximately
15 cm cranio-caudally. Due to clinical presentation and laboratory⁎ Corresponding author at: Department of Pathology, New York Medical College,
Westchester Medical Center, 100 Woods Road, Valhalla, NY 10595, USA.
E-mail address: sabinanb@gmail.com (S. Hajiyeva).
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(HLH).
Bone marrow biopsy and aspiration were performed. Histological
examination of bone marrow core revealed a hypercellular bone mar-
row, with a cellularity of 70–80%. Majority of the hematopoietic ele-
ments were placed by sheets of medium-sized atypical cells with
medium to large nuclei with open chromatin, irregular nuclear
membranes, prominent nucleoli, and increased mitotic. Marked tumor
necrosis was seen (Fig. 1). Immunohistochemical studies were per-
formed using antibodies against CD3, CD5, CD20, CD79a, PAX-5, MPO,
CD117, CD30, CD45, ALK-1, CD 138, Kappa, Lambda, CD4, CD8, MUM-
1, EMA, EBV, CD43, CD68, CD 56, TdT, CD123 and TCL1. It revealed
that neoplastic cells were positive for CD4, CD 56, CD45, CD43 and
CD68, while they were negative for all other markers. Flow cytometry
analysis of CD45 positive gate with medium to low side scatter reveals
an abnormal immature population of cells (~30% of total) expressing
CD4, CD56 and CD33 while they are negative for MPO, CD123 and
CD34 (Fig. 2); this was consistent with H&E diagnosis. Based on these
ﬁndings bone marrow diagnosed as involved by atypical myeloid
neoplasm.
For cytogenetic analysis, an unstimulated and short-term culture
was performed using bone marrow aspirate. The karyotype demon-
strated an abnormal male karyotype with two clones. The ﬁrst clone
(13/20 cells) had an extra copy of chromosome 8 in 13 out of 20 meta-
phase cells analyzed: 47,XY,+8[13]/46,XY[7] (Fig. 3). Fluorescence in
situ hybridization (FISH) analysis was performed using a variety of
DNA probes. FISH analyses detected three copies of the centromere 8-
speciﬁc signal in 22% (44/200) of nuclei examined, suggestive of trisomy
8 (Fig. 3).
3. Discussion
The ﬁrst case of BPDCN was reported in 1994 [8] and since then,
fewer than 200 cases have been described in the literature. BPDCN typ-
ically manifests in middle-aged or older men, the median age being
65 years at diagnosis. It is a very rare entity and reportedly occurs at
an incidence of 0.76% vs. acute myelogenous leukemia and 0.27% vs.
non-Hodgkin's lymphoma [9].
BPDCN has a poor prognosis. The mean survival time of patients is
reportedly 14.0 to 16.7 months, and the 2- and 5-year overall survival
rates are 17% to 33% and 2% to 6%, respectively [10,11]. Early symptoms
include skin lesions, which are present in more than 90% of patients,
along with nodules, erythematous plaques, and bruise-like areas. Bone
marrow inﬁltration is absent in 70% of patients at the initialnse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Laboratory examination on admission.
Peripheral Blood Chemistry
White blood cell 3400/uL Total Protein 6.3 g/dL Fe 60 μg/dL
Neutrophil 61% Albumin 3.3 g/dL UIBC 194 μg/dL
Lymphocyte 24% AST 22 IU/L Ferritin 14,095.0 ng/mL
Monocyte 14% ALT 18 IU/L β2-microglobulin
3.0 μg/mL
Metamyelocytes 1% ALP 225 IU/L Coagulation
Red blood cell
3.25 × 106/uL
LDH 362 IU/L PT-INR 1.25




Reticulocyte 1.7 Na 127 mEq/L D-Dimer 29.4 mg/L FEU
Platelet 62 × 103/uL K 3.5 mEq/L
Uric Acid 8.1 mg/dL
2 S. Hajiyeva et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxexamination, but lymph node and bonemarrow inﬁltration occurs dur-
ing the disease course in 72% of patients, resulting in leukemic change
and eventual death in many cases [10,12,5].
Cases presenting primarily as leukemia without cutaneous involve-
ment is a rarity. And there are only few studies describing the compre-
hensive immunophenotypic pattern of BPDCN in the bone marrow.
Flow cytometry is preferred over immunohistochemical analysis since it
allows for the examination of more markers and their intensity determi-
nation. The diagnosis relies on the immunophenotypic features of thema-
lignant cells. The expression of CD4, CD56, and CD123 in the absence of T-Fig. 1. Histopathological examination of a bone marrow biopsy. (A) Diffuse inﬁltrate occupying
(B) Higher ampliﬁcation of the large blastic cells with large irregular nuclei (H&E; magniﬁcatio
×20). (D) Immunohistochemically neoplastic cells are positive for CD 56 (magniﬁcation, ×20)
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sis implies an appropriate panel of antibodies; in contrast, insufﬁcient
knowledge on this entity and inadequate immunophenotypic investiga-
tion can lead to the misdiagnosis of a different leukemia.
Genetic aberrations of BPDCN have been studied in only a limited
number of cases. Thus far, genetic mechanisms associated with BPDCN
are not well understood. Chromosomal abnormalities and gene muta-
tions associated with other myeloid and lymphoid neoplasms were
identiﬁed in some BPDCN cases [13–16].
BPDCN and MPO negative acute myeloid neoplasm with aberrant
expression of CD56 marker (as was also the case in our patient) and
bone marrow involvement is of important consideration in differential
diagnosis. The distinction between an acute myeloid neoplasm and
BPDCN, can be extremely difﬁcult in view of the similarities in the clin-
ical presentations, morphollogic appearance of tumor cells and
immunophenotypes. The problem of establishing a diagnosis can be
compounded further with a possible loss of CD4 and CD56 antigens in
cases of BPDCN [1,5]. The differentiation between BPDCN and an acute
myeloid neoplasm is based on the application of speciﬁc CD myeloid
markers CD33, MPO and lysozyme and speciﬁc dendritic cell-
associated antigens CD123, CD303, CD2AP and TCL1. The expression of
at least 3 of the markers CD4, CD56, CD123, CD303, CD2AP and TCL1
are necessary for the diagnosis of BPDCN [2–5]. Negativity ofMPO is im-
portant but not discriminating marker.
After the diagnosis of acute myeloid neoplasm was established on
bonemarrow cytology and ﬂowcytometry, we used additional markers
CD123 and TCL1which showed negativity. So, it was concluded that the
patient had AML, M4 which at onset was presented as MPO -, CD4+,the entire bonemarrow (hematoxylin and eosin stain [H&E]; original magniﬁcation, ×4).
n, ×40). (C) Immunohistochemically neoplastic cells are positive for CD4 (magniﬁcation,
.
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Fig. 2.Bonemarrowmultiparametricﬂow cytometry. Flow cytometry dot plots of bonemarrowaspirate showing atypicalmyeloid cells (blue dots), expressing CD45, CD4, CD56, CD33 and
negative CD123. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
3S. Hajiyeva et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxand CD56+ myeloid neoplasm. Our patient had an initially good re-
sponse to treatment, with complete remission lasting around 2months.
However, the disease soon progressed and he died with refractory my-
eloid leukemia 3 months after the initial diagnosis.Conﬂict of interest
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